Logo
x

Search

Subscribe Now

Label

AstraZeneca's Forxiga (dapagliflozin) Receive NMPA's Approval for Label Update to Include Data of P-III DECLARE-TIMI 58 Study

AstraZeneca's Forxiga (dapagliflozin) Receive NMPA's Approval for Label Update to Include Data of P-III DECLARE-TIMI 58 Study

  • October 28, 2020
AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal Data for Forxiga (dapagliflozin) in EU

AstraZeneca Reports Label Update with Positive Cardiovascular Outcomes and Renal Data for Forxiga (dapagliflozin) in EU

  • August 5, 2019
Samsung Bioepis Reports EU Label Update with Extended Storage Conditions for Imraldi (biosimilar- adalimumab)

Samsung Bioepis Reports EU Label Update with Extended Storage Conditions for Imraldi (biosimilar- adalimumab)

  • June 28, 2019
Merck's Keytruda (pembrolizumab) Receives FDA's Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC)

Merck's Keytruda (pembrolizumab) Receives FDA's Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell...

  • April 12, 2019
Vertex's Kalydeco (ivacaftor) Receives FDA's Expanded Label Approval for Cystic Fibrosis (CF) Aged 12 to < 24 Months

Vertex's Kalydeco (ivacaftor) Receives FDA's Expanded Label Approval for Cystic Fibrosis (CF) Aged 12 to < 24 Months

  • November 30, 2018
Merck's Keytruda (pembrolizumab) Receives Expanded Label Approval for 1L nonsq. mNSCLC- with No EGFR and ALK Genomic Tumor

Merck's Keytruda (pembrolizumab) Receives Expanded Label Approval for 1L nonsq. mNSCLC- with No EGFR and ALK Genomic Tumor

  • August 21, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.